Akari Therapeutics Completes $5.5M Private Placement, Issues Final 980K ADSs
AKTX has more than doubled off its 52-week low of $3.015 on light trading volume (0.1× avg).
Summary
Akari Therapeutics has completed the final tranche of its previously announced $5.5 million private placement, issuing 980,395 ADSs. This consolidates the second and third closings, bringing the total ADSs issued in this offering to 1,470,588. This financing was initially announced in May at $3.74 per ADS, a significant discount to the current market price. The completion of this capital raise is crucial for the company's immediate liquidity, especially given its Q1 2026 going concern warning and cash runway extending only into June. However, the offering is highly dilutive relative to the company's small market capitalization. Shareholder approval for associated warrants (Series H, I, and J) is pending at the June 30, 2026 annual meeting.
At the time of this announcement, AKTX was trading at $9.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.9M. The 52-week trading range was $3.02 to $49.60. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.